Top 10 Stocks to Watch — Wednesday, August 26

Three themes dominated Tuesday's tape: the nuclear power trade roared back to life, biotech caught a serious bid on the cancer vaccine story, and AI infrastructure got a fresh deal catalyst. The S&P 500 closed at 7,677 (+0.32%), but the index-level numbers hide the violence underneath. Nasdaq led with a +0.66% gain, the Russell 2000 added +0.50%, and sector leaders in nuclear and biotech were running double digits while Dick's Sporting Goods fell 30% on earnings in the same session.

Wednesday opens with oil down another 2.5% (WTI at $80.29), gold holding near record highs at $4,679/oz, and the long bond catching a bid (TLT +1.1% Tuesday) — a combination that suggests the market is pricing in some slowing while still chasing high-momentum growth names. The VIX ticked up to 15.69, a modest hedge, not a panic signal. The setup is constructive for the names below, with the usual caveat that momentum sectors can reverse hard on any macro surprise.

All prices below are prior session close (Tuesday, Aug. 25) unless noted as pre-market. Watch levels and triggers described here are scenarios to monitor — not recommendations to buy at any specific price.

1. Moderna (MRNA) — $158.83 | +14.36%

The Moderna-Merck personalized cancer vaccine trade has been one of the biggest stories in biotech this year, and Tuesday was another leg of it. MRNA gained over $19 to close at $158.83, extending what Bloomberg called a "129% surge for the week" in coverage from last week. The underlying catalyst is the mRNA-4157/V940 program — a joint venture with Merck that produces individualized neoantigen vaccines targeting a patient's specific tumor mutations. Phase III data in melanoma has been compelling, and investors are now pricing in a market opportunity measured in billions if the approach translates to other solid tumors.

The stock still has room to the 52-week high at $176.66, and it's sitting 461% above its 52-week low — a reminder that this is not a new story, but the momentum is real and backed by hard clinical data. Merck's deep commercial infrastructure is a key asymmetry most other biotech partnerships don't have.

Watch for: Any FDA calendar updates on the cancer vaccine program, or further Merck commentary on the partnership. A close above $165 on heavy volume would signal the run is still intact.

2. Oklo Inc. (OKLO) — $44.27 | +11.54% (pre-market indicated +3%)

The nuclear renaissance is no longer a thesis — it's a trade with specific near-term catalysts. Oklo closed at $44.27 after a strong Tuesday session, and was indicated another ~3% higher in early pre-market on Wednesday per analyst coverage. The catalyst stack here is layered: the company's Groves isotope test reactor achieved first criticality last month (a genuine technical milestone, not a press release), the Department of Energy's Nuclear Lifecycle Innovation Campus program has shortlisted five states, and the company ended Q2 with $3 billion in liquidity — enough runway to reach commercial operation without dilutive raises.

What makes Oklo interesting relative to other nuclear plays is vertical integration: power, fuel, and isotopes, plus a stated path toward HALEU (high-assay low-enriched uranium) fuel production. This is not a royalty or a speculative pre-revenue name — it has real contracts and operational milestones.

Watch for: Any DOE NLIC announcement or additional AI data center power agreements (the hyperscaler demand is the rocket fuel under the whole nuclear sector). The 52-week range of $36.61–$193.84 shows just how much volatility this name carries — position size accordingly.

3. Super Micro Computer (SMCI) — ~$35.36 close | +9.35% peak

SMCI gapped up 9% in early Tuesday trading after Cisco announced an expansion of its Secure AI Factory — an AI hardware platform built jointly with Super Micro and NVIDIA. Simultaneously, Taiwan authorities cleared the legal overhang from an earlier investigation involving smuggling allegations against company employees. The dual catalyst (fresh demand deal + overhang removal) is the kind of setup that creates fast, sharp moves.

The catch: SMCI gave back much of the gain by the afternoon, fading from the $38+ open to close around $35.36 (-5% from where it peaked). That fade is worth watching — it often indicates either short-term profit-taking on a genuine catalyst or skepticism about whether the Cisco deal moves the needle for a company at SMCI's revenue scale. At $35, it's trading at about 11x trailing earnings — cheap for an AI server company, if the execution risk stays manageable after last year's accounting controversies.

Watch for: If SMCI opens Wednesday above $36 and holds, the Cisco deal is being re-rated. A break back below $34 would likely confirm sellers are in control. The analyst consensus target sits at $42.38.

The rest of this briefing is for paid members: the full ranked list of tickers 4 through 10, including the uranium fuel play with a record backlog and a pre-market setup, the small biotech breaking to new 52-week highs on Phase II data, the fintech name riding the Trump Accounts and crypto tailwind, and the precious metals leveraged miner with gold at $4,679 — plus watch levels and triggers for each.

AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.

Unlock the full briefing →